Related Experiment Video

Updated: May 6, 2026

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells
07:22

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells

Published on: March 28, 2013

38.4K

Refocusing Peroxisome Proliferator Activated Receptor-α: A New Insight for Therapeutic Roles in Diabetes

Hannah Seok1, Bong Soo Cha

  • 1Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.

Diabetes & Metabolism Journal
|November 8, 2013
PubMed

Insights

New therapeutic strategies targeting peroxisome proliferator activated receptor-alpha (PPAR-α) show promise for managing diabetic complications. PPAR-α activation may offer a novel approach to address remaining cardiovascular risks in diabetes.

Area of Science:

  • Endocrinology and Metabolism
  • Molecular Biology
  • Cardiovascular Research

Background:

  • Despite glucose-lowering treatments, macrovascular and microvascular complications persist in diabetes.
  • Peroxisome proliferator activated receptor-alpha (PPAR-α) is implicated in lipid metabolism and inflammation relevant to diabetic complications.

Purpose of the Study:

  • To review the metabolic functions of PPAR-α.
  • To summarize clinical data on PPAR-α agonists in diabetes.
  • To discuss the therapeutic potential of PPAR-α activation for diabetic complications.

Main Methods:

  • Literature review of metabolic roles of PPAR-α.
  • Analysis of clinical studies investigating PPAR-α agonists in diabetic patients.
  • Discussion of the implications of PPAR-α activation in diabetes.

Main Results:

  • PPAR-α regulates key metabolic pathways including lipid homeostasis and fatty acid oxidation.
  • Clinical studies provide insights into the efficacy and safety of PPAR-α agonists.
  • PPAR-α activation influences inflammatory and vascular processes linked to diabetic pathology.

Conclusions:

  • PPAR-α plays a significant role in metabolic regulation pertinent to diabetes.
  • PPAR-α agonists represent a potential therapeutic avenue for managing diabetic complications.
  • Further research is warranted to fully elucidate and optimize PPAR-α targeted therapies.
Keywords:
DiabetesDiabetes complicationsFibric acidsPeroxisome proliferator activated receptor agonists

More Related Videos

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

1.1K
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

15.9K

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
Peroxisomes01:24

Peroxisomes

Peroxisomes are specialized organelles present in fungi, plant, and animal cells. It can vary in number, size, morphology, and activity depending on the type of tissue and the nutritional state of the cell. For example, cells with active lipid metabolism, such as adipocytes, neurons, and hepatocytes, have more peroxisomes than other cells in the body. Besides their primary role in breaking down complex organic molecules, peroxisomes can also synthesize specific macromolecules and participate in...
13.6K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.4K
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
6.0K
Chronic Pancreatitis II: Pathophysiology01:21

Chronic Pancreatitis II: Pathophysiology

Chronic pancreatitis is a progressive and irreversible inflammation of the pancreas, most often caused by long-term alcohol abuse, but it can also be related to ductal obstruction, smoking, or genetic factors.Chronic pancreatitis occurs when the pancreas is repeatedly exposed to harmful agents like alcohol, smoking, ductal obstruction, or genetic predisposition. These factors lead to the release of toxic metabolites and inflammatory cytokines, sustaining chronic inflammation in the pancreatic...
35
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
36